Bisphosphonate or RANK-L inhibitor for tumour-induced hypercalcaemia?

Netherlands Journal of Medicine

Volumn 70, Issue 5, 2012, Pages 250-251

  Bech, A ^a   Essink, G ^a   de Boer, H ^a  

^a RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; COLECALCIFEROL; CREATININE; DENOSUMAB; FLUORODEOXYGLUCOSE F 18; PAMIDRONIC ACID; PARATHYROID HORMONE; SODIUM CHLORIDE;

ADULT; CALCIUM BLOOD LEVEL; CANCER PATIENT; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CREATININE BLOOD LEVEL; DRUG CHOICE; FLUID RESUSCITATION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY FUNCTION; LETTER; LYMPH NODE METASTASIS; MALE; NEPHRECTOMY; PARATHYROID HORMONE BLOOD LEVEL; SINGLE DRUG DOSE; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

BONE DENSITY CONSERVATION AGENTS; CARCINOMA, RENAL CELL; DIPHOSPHONATES; HUMANS; HYPERCALCEMIA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RANK LIGAND;

EID: 84866135458     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Pepper K, Jaowattana U, Starsiak MD, et al. Renal cell carcinoma presenting with paraneoplastic hypercalcemic coma: a case report and review of the literature. J Gen Intern Med. 2007;22:1042-6.
2. Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res. 2005;15:57-62.
3. Motellón JL, Jiménez FJ, de Miguel F, et al. Relationship of plasma bone cytokines with hypercalcemia in cancer patients. Clin Chim Acta. 2000;302:59-68.
4. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2005;20:2275-82.
5. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008;74:1385-93.